The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion ...

At the world's largest cancer research meeting, new data were plentiful. But this year, there was also a focus on grief.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation and legislation. He is also the author of the morning Pharmalittle newsletter ...

STAT is co-publishing this with Undark. This story was supported by the Pulitzer Center. In 1975, in a medical school classroom in what was then the Socialist Federal Republic of Yugoslavia, Predrag ...

Older adults on Medicare can get Wegovy and Zepbound for $50 a month, starting in July. But the agency still is not sharing ...

A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Tara covers the business of health care. Her stories focus on hospitals, doctors, and how their business practices affect patients — especially when private equity gets involved. She also writes about ...

By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results ...

Oncologists are capable of some raucous applause, but they don’t bestow it upon just anyone. Today saw one of those coveted ...